ID
22333
Description
A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1 This form is to be completed in Screening Period 1 and after 12 Months +/- 1 week.
Link
https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Keywords
Versions (2)
- 5/22/17 5/22/17 -
- 5/30/17 5/30/17 -
Uploaded on
May 30, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Serum HCG Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Serum HCG Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Similar models
Serum HCG Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
C2348235 (UMLS CUI [1,2])
C3146298 (UMLS CUI [1,2])
C0430060 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
C0430060 (UMLS CUI [3,1])
C0040223 (UMLS CUI [3,2])
No comments